UK anticoagulants market is estimated to grow at a CAGR of 7.0% during the forecast period. Rising incidences of CVD have been witnessed in the country which is contributing to the growth of the market. As per the British Heart Federation (BHF), in 2018, nearly 7.4 million people suffering from heart and circulatory diseases in the UK. The growing aging population and sedentary lifestyle habits have resulted in the rising incidences of heart and circulatory diseases in the country. This, in turn, is resulting in an increasing demand for anticoagulants that are used to prevent the blood from clotting as rapidly or as potentially as normal. Anticoagulants are also known as blood thinners. These medications are used for the treatment and prevention of blood clots that may occur in the blood vessels. 

Visit for Global Anticoagulants Market Report at: https://www.omrglobal.com/industry-reports/anticoagulants-market

The market is segmented based on type and application. Based on type, the market is classified into novel oral anticoagulants (NOACs), vitamin k antagonist, and heparin, and low molecular weight heparin (LMWH). Based on application, the market is classified into a pulmonary embolism, atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis, and others. As per the BHF, atrial fibrillation is a major cause of stroke and one of the most common forms of abnormal heart rhythm (arrhythmia). In 2018, nearly 1.4 million people in the country have been diagnosed with atrial fibrillation. This is driving the adoption of anticoagulants that are utilized for the prevention of blood clots and atrial fibrillation (AF) is the most common condition in which blood clots are formed. Therefore, warfarin is used as the most commonly utilized vitamin K antagonist (VKA) to reduce the risk of stroke in certain AF patients with risk factors.

Some key players in the market include AstraZeneca Plc, Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH. In December 2019, the Bristol-Myers Squibb-Pfizer Alliance declared outcomes from retrospective real-world data analyses which reports outcomes on the safety and efficacy of Eliquis (apixaban) than low molecular weight heparin (LMWH) or warfarin to treat venous thromboembolism (VTE) in patients with active cancer. Eliquis reduces blood clot formation and thrombin generation by impeding Factor Xa, a major blood-clotting protein. It is approved for multiple indications in the US based on safety and effectiveness data from several Phase 3 clinical trials.

Research Methodology

The market study of the UK anticoagulants market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. UK Anticoagulants Market Research and Analysis by Type
2. UK Anticoagulants Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the UK anticoagulants market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK anticoagulants market.
• Insights about market determinants that are stimulating the UK anticoagulants market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.